EXAGEN INC. (XGN)

Exagen is a specialty clinical laboratory company focused on autoimmune disease diagnostics, primarily serving rheumatologists in the United States. The San Diego-based firm operates a testing business centered on its AVISE branded diagnostic platform, which uses proprietary cell-bound complement activation products (CB-CAPs) technology to help clinicians diagnose lupus, rheumatoid arthritis, and other connective tissue diseases more quickly and accurately.

The Core Business

Exagen makes money through laboratory testing services. When a rheumatologist orders an AVISE test for a patient with suspected autoimmune disease, Exagen performs the lab work and bills insurance for the test. The company’s flagship offering, AVISE CTD, launched in 2012, measures specific biomarkers—particularly complement activation patterns—that distinguish between different autoimmune conditions presenting with similar symptoms. A patient’s symptoms might point to lupus, Sjögren’s disease, scleroderma, or mixed connective tissue disease; the AVISE CTD test helps narrow down which actual disease is present. Beyond CTD, the platform includes AVISE MTX, which monitors methotrexate levels in rheumatoid arthritis patients, and AVISE Anti-CarP, a prognostic test that identifies RA patients likely to develop severe disease.

Revenue per test averages around $320. Gross margins in recent years have ranged from the mid-40s to upper-50s percent, a structure typical for specialty diagnostics where reagent and labor costs are offset by relatively high billable amounts and, increasingly, established reimbursement pathways. Exagen reached a milestone of one million cumulative AVISE CTD tests completed, reflecting a decade of steady adoption among U.S. rheumatologists.

What Makes It Distinctive

The company’s moat rests on the intellectual property and clinical evidence behind CB-CAPs technology. The complement system is a part of immune function implicated in autoimmune disease pathogenesis; measuring its activation in circulating cells offers a window into disease activity and type. Exagen has published clinical studies supporting the diagnostic utility of AVISE tests, which helps establish medical-community acceptance and supports reimbursement negotiation with payers. The company maintains a direct sales force that educates rheumatology practices on test ordering, a typical and cost-intensive model for specialty lab diagnostics.

Competition in autoimmune diagnostics comes from larger, diversified laboratory companies (LabCorp, Quest) that also run rheumatology panels, as well as regional labs and point-of-care vendors. Exagen’s differentiation depends on the perceived clinical value of its specific biomarkers and its operational focus—it does not operate as a generalist lab but as a specialist, which can translate to deeper expertise and higher adoption within its narrow niche. The risk is that a larger competitor could copy or license the technology, or that an alternative diagnostic approach (such as genetic testing or imaging) could reduce the need for serological testing.

Revenue and Scale

Exagen’s business is relatively small and stable within the broader diagnostics market. In recent years, the company has reported annual revenues in the $45–55 million range, with most of that revenue concentrated in the United States. Growth has been modest single-digit to low double-digit percentages. The installed base of ordering rheumatologists is in the hundreds, not thousands, meaning that penetration still has considerable room. However, the typical rheumatology practice already orders autoimmune testing—the question for Exagen is gaining preference within that ordering pattern. Insurance reimbursement for AVISE tests is well established, which supports predictable revenue, but this also means the company must manage reimbursement codes and payer contracts closely.

Pressures and Uncertainties

The company faces exposure to changes in medical practice patterns and insurance reimbursement. If a major payer significantly reduces reimbursement for complement-based testing or changes coding rules, revenue could contract. Clinical practice guidelines could shift away from serological testing or toward competing methodologies. The company’s limited scale also means that loss of a major institutional customer or laboratory partnership can materially affect results. Exagen’s balance sheet and profitability have trended positive in recent years, but as a small-cap publicly traded company, it relies on capital markets for growth funding, making it sensitive to risk appetite in biotech and diagnostics equities.

The competitive moat is real but narrowly defined. Larger competitors have the operational scale and distribution to bundle AVISE-like tests with broader panels; smaller regional labs can offer lower-cost alternatives. Exagen’s defense is clinical differentiation and deep rheumatology focus, but these are not unassailable. Patent protection on CB-CAPs methodology extends the runway, but patent cliffs can become material.

How to Research It

Start with Exagen’s 10-K filing, which details segment revenue, test volumes, reimbursement rates, and payer mix. Watch for quarterly reports discussing ordering trends, average selling price per test, and gross margin trends—these are the operational metrics that drive the business. Review investor presentations at conferences, which typically walk through the addressable market (number of U.S. rheumatologists, annual patient volume needing diagnosis, current penetration). Look at published clinical studies supporting AVISE, both company-sponsored and independent, to gauge the strength of the evidence base and adoption likelihood among practitioners. Track quarterly earnings calls for discussion of payer contract renegotiations, new test development, and volume trends. Periodically check Nasdaq data on trading volume and insider transactions; small-cap diagnostic companies can see meaningful valuation swings on modest news.